IntelGenx Granted Patent Protecting RIZAPORT™ Oral Film for Migraines

IntelGenx Corp., (TSXV:IGX, OTCQX:IGXT) announced the has been granted a patent protecting Rizaport™, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. This patent protects the composition of Rizaport™ and will be listed in the Orange Book upon approval of the product by the FDA.
According to the Dr. Horst G. Zerbe, President and CEO of IntelGenx:

“Rizaport™ is the first patent allowed for an oral film for the treatment of migraine. We are committed to bringing Rizaport™ to market as soon as possible as we believe it will be a beneficial treatment for patients suffering from migraines. The patent allowance is one more systematic step towards strengthening our patent portfolio supporting IntelGenx’s proprietary VersaFilm™ technology. This will now further enable IntelGenx to accelerate our ongoing partnering efforts in the USA and abroad.

Click here to view the full press release.